WallStSmart

Cardiol Therapeutics Inc Class A (CRDL)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

UTHR leads profitability with a 41.6% profit margin vs 0.0%. UTHR earns a higher WallStSmart Score of 61/100 (C+).

CRDL

Avoid

17

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -14.58

UTHR

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 9.0Value: 6.0Quality: 7.8
Piotroski: 5/9Altman Z: 8.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CRDL.

UTHRUndervalued (+0.8%)

Margin of Safety

+0.8%

Fair Value

$479.95

Current Price

$497.11

$17.16 discount

UndervaluedFair: $479.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CRDL1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

UTHR5 strengths · Avg: 9.4/10
Profit MarginProfitability
41.6%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
42.2%10/10

Strong operational efficiency at 42.2%

Altman Z-ScoreHealth
8.5610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 20 in profit

P/E RatioValuation
17.9x8/10

Attractively priced relative to earnings

Areas to Watch

CRDL4 concerns · Avg: 3.8/10
Price/BookValuation
13.3x4/10

Trading at 13.3x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$233.06M3/10

Smaller company, higher risk/reward

UTHR2 concerns · Avg: 3.0/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : CRDL

The strongest argument for CRDL centers on Debt/Equity.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.

Bear Case : CRDL

The primary concerns for CRDL are Price/Book, Revenue Growth, EPS Growth.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

CRDL profiles as a value stock while UTHR is a declining play — different risk/reward profiles.

CRDL carries more volatility with a beta of 0.61 — expect wider price swings.

CRDL is growing revenue faster at 0.0% — sustainability is the question.

UTHR generates stronger free cash flow (206M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (61/100 vs 17/100), backed by strong 41.6% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardiol Therapeutics Inc Class A

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Cardiol Therapeutics Inc., a clinical-phase biotechnology company, focuses on the research and development of anti-inflammatory therapies for the treatment of cardiovascular diseases (CVD). The company is headquartered in Oakville, Canada.

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?